AGMB-129 is under clinical development by AgomAb Therapeutics and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGMB-129’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGMB-129 overview
AGMB-129 is under development for the treatment of crohn's disease. It is administered orally as a capsule. The drug candidate acts by targeting ALK5.
It was under development for colon cancer.
AgomAb Therapeutics overview
AgomAb Therapeutics (AgomAb) is a biotechnology company that develops growth factor mimetic agonistic monoclonal antibodies to regenerate damaged tissues and produced a comprehensive preclinical package. The company product pipeline includes AGMB -129, AGMB -447, AGMB -101 and AGMB -101. Its pipeline treats to cronh’s disease, idiopathic pulmonary fibrosis, organ failure and fibrotic indication. AgomAb provides novel treatment to restore organ functions. The company combines new scientific insights with robust drug development and build a broad clinical pipeline of differentiated programs with disease-modifying potential in severe organ failure and fibrotic diseases. The company operates its research laboratory in Italy and Spain. AgomAb is headquartered in Ghent, Belgium.
For a complete picture of AGMB-129’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
